Angiotensin-converting enzyme and cardiovascular disease risk

Current Opinion in Lipidology

Volumn 10, Issue 5, 1999, Pages 407-415

  O'Malley, Jean Pruss ^a   Maslen, Cheryl L ^a   Illingworth, D Roger ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE;

ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DNA POLYMORPHISM; GENETIC RISK; GENOTYPE; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; REVIEW;

CARDIOVASCULAR DISEASES; GENETIC HETEROGENEITY; HUMANS; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 0033390897     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199910000-00005     Document Type: Review

References (74)

1. 1 Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F, Soubrier F. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 1992; 51:197-205.
2. 2 Celentano A, Mancini FP, Crivano M, Palmieri V, Ferrara LA, De Stefano V, et al. Cardiovascular risk factors, angiotensin-converting enzyme gene polymorphism, and left ventricular mass in systemic hypertension. Am J Cardiol 1999; 83:1196-1200.
3. 3 Atlas SA. The renin - angiotensin system revisited: classical and nonclassical pathways of angiotensin formation. Mount Sinai J Med 1998; 65:87-96. This review summarizes the current views on the regulation of the conversion of angiotensin I to angiotensin II in the blood and in tissue renin - angiotensin systems.
4. 4 Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation 1998; 97:1411-1420. This is a concise but thorough review of the pharmacology and clinical effects of ACE-inhibitor therapy.
5. 5 Yousef S, Lonn E. Anti-ischaemic effects of ACE inhibitors: review of current evidence and ongoing clinical trials. Eur Heart J 1998; 19 (Suppl J):J36-J44.
6. 6 Ferrari R. Effect of ACE inhibition on myocardial ischaemia. Eur Heart J 1998; 19 (Suppl J):J30-J35. This review summarizes the mechanisms which might explain the reduction of ischaemic events observed in clinical trials of ACE-inhibitors.
7. 7 Mancini GB. Role of angiotensin-converting enzyme inhibition in reversal of endoothelial disfunction in coronary artery disease. Am J Med 1998; 105:40S-47S. This is an excellent summary of the data from the TREND and QUIET multicenter trials of the beneficial effects of quinapril therapy on endothelial dysfunction.
8. 8 Hoshida S, Nishida M, Yamashita N, Igarashi J, Aoki K, Hori M, et al. Vascular angiotensin-converting enzyme activity in cholesterol-fed rabbits: effects of enalapril. Atherosclerosis 1997; 130:53-59.
9. 9 Kowala MC, Grove RI, Aberg G. Inhibitors of angiotensin converting enzyme decrease early atherosclerosis in hyperlipidemic hamsters. Fosinipril reduces plasma cholesterol and captopril inhibits macrophage-foam cell formation independently of blood pressure and plasma lipids. Atherosclerosis 1991; 108:61-72.
10. 10 Kowala MC, Valentine M, Recce R, Beyer S, Goller N, Durham S, Aberg G. Enhanced reduction of atherosclerosis in hamsters treated with pravastatin and captopril: ACE in atheromas provides cellular targets for captopril. J Cardiovasc Pharmacol 1998; 32:29-38.
11. 11 Ohishi M, Ueda M, Rakugi H, Naruko T, Kojima A, Okamura A, et al. Enhanced expression of angiotensin-converting enzyme is associated with progression of coronary atherosclerosis in humans. J Hypertens 1997; 15:1295-1302.
12. 12 Villard E, Tiret L, Visvikis S, Rakotovao R, Cambien F, Soubrier F. Identification of new polymorphisms of the angiotensin I-converting enzyme (ACE) gene, and study of their relationship to plasma ACE levels by two-QTL segregation-linkage analysis. Am J Hum Genet 1996; 58:1268-1278.
13. 13 McKensie CA, Julier C, Forrester T, McFarlane-Anderson N, Keavney B, Lathrop GM, et al. Segregation and linkage analysis of serum angiotensin I-converting enzyme levels: evidence for two quantitative loci traits. Am J Hum Genet 1995; 57:1426-1435.
14. 14 Lee EJD. Population genetics of the angiotensin-converting enzyme in Chinese. Br J Clin Pharmacol 1994; 37:212-214.
15. 15 Nakai K, Itoh C, Miura Y, Hotta K, Musha T, Itoh T, et al. Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with serum ACE concentration and increased risk for CAD in the Japanese. Circulation 1994; 90:2199-2202.
16. 16 Foy CA, McCormack LJ, Knowler WC, Barrett J, Catto A, Grant P. The angiotensin-I converting enzyme (ACE) gene I/D polymorphism and ACE levels in Pima Indians. J Med Genet 1996; 33:336-337.
17. 17 Bloem LJ, Manatunga AK, Pratt JH. Racial difference in the relationship of an angiotensin I-converting enzyme gene polymorphism to serum angiotensin I-converting enzyme activity. Hypertension 1996; 27:62-66.
18. 18 Oidl K, Strelcova L, Znojil V, Vacha J. Angiotensin I-converting enzyme (ACE) polymorphism and ABO blood groups as factors codetermining plasma ACE activity. Exp Hematol 1996; 24:790-794.
19. 19 Foy CA, Rice GI, Ossei-Gerning N, Mansfield MW, Grant PJ. Angiotensin-converting enzyme (ACE) gene polymorphisms in patients characterized by coronary artery disease. Hum Genet 1997; 100:420-425.
20. 20 Staessen JA, Wang JG, Ginocchio G, Petrov V, Saavedra AP, Soubrier F, et al. The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular risk. J Hypertens 1997; 15:1579-1592.
21. 21 Schunkert H. Polymorphism of the angiotensin-converting enzyme gene and cardiovascular disease. J Mol Med 1997; 75:867-875.
22. 22 Butler R, Morris D, Struthers AD. Angiotensin-converting enzyme gene polymorphism and cardiovascular disease. Clin Sci 1997; 93:391-400.
23. 23 Kamitani A, Rakugi H, Higaki J, Ohishi M, Shi S-J, Takami S, et al. Enhanced predictability of myocardial infarction in Japanese by combined genotype analysis. Hypertension 1995; 25:950-953.
24. 24 Fujimora T, Yokota M, Kato S, Hirayama H, Tsunekawa A, Inagaki H, et al. Lack of association of angiotensin converting enzyme gene polymorphism or serum enzyme activity with coronary artery disease in Japanese subjects. Am J Hypertens 1997; 10:1384-1390.
25. 25 Ko Y-L, Ko Y-S, Wang S-M, Chu P-H, Teng M-S, Cheng N-J, et al. Angiotensinogen and angiotensin-I converting enzyme gene polymorphisms and the risk of coronary disease in Chinese. Hum Genet 1997; 100:210-214.
26. 26 Arbustini E, Grasso M, Fasani R, Klersy C, Diegoli M, Porcu E, et al. Angiotensin converting enzyme gene deletion allele is independently and strongly associated with coronary atherosclerosis and myocardial infarction. Br Heart J 1995; 74:584-59.
27. 27 Arca M, Pannitteri PF, Campagna F, Candeloro A, Montali A, Cantini R, et al. Angiotensin-converting enzyme gene polymorphism is associated with coronary atherosclerosis and myocardial infarction in a sample of Italian patients. Eur J Clin Invest 1998; 28:485-490. Although this recent study of the prevalence of the ACE DD genotype did not observe an association between myocardial infarction and the ACE DD genotype in 394 Italian patients undergoing coronary angiography, the results were homogeneous with the slight overall association observed in European countries. Data from this study were included in the Mantel-Haenszel calculation of the overall myocardial infarction odds ratio of 1.20 for DD versus DI + II (Table 1).
28. 28 Evans AE, Poirier O, Lee F, Lecerf L, McCrum E, Falconer T, et al. Polymorphisms of the angiotensin-converting-enzyme gene in subjects who die from coronary heart disease. Quart J Med 1994; 87:211-214.
29. 29 Cambien F, Poirier O, Lecerf L, Evans A, Combou JP, Arveiler D, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359:641-644.
30. 30 Ferrieres J, Ruidavets J-B, Fauvel J, Perret B, Taraszkiewicz D, Fourcade J, et al. Angiotensin I-converting enzyme gene polymorphism in a low-risk European population for coronary heart disease. Atherosclerosis 1999; 142:211-216. This recent study of the association of the ACE DD genotype with myocardial infarction and angiographically confirmed stenosis recruited individuals from Toulouse, France, which was the source of one of the ECTIM study populations in which the original observation of increased risk for myocardial infarction in ACE DD patients was observed. The results, while negative, were homogeneous with those observed in other European countries and data from this study were included in the Mantel-Haenszel calculation of the overall European odds ratio for myocardial infarction (Table 1).
31. 31 Friedl W, Krempler F, Paulweber B, Pichler M, Sandhofer F. A deletion polymorphism in the angiotensin converting enzyme gene is not associated with coronary heart disease in an Austrian population. Atherosclerosis 1995; 112:137-143.
32. 32 Leatham E, Barley J, Redwood S, Hussein W, Carter N, Jeffery S, et al. Angiotensin-I converting enzyme (ACE) polymorphism in patients presenting with myocardial infarction or unstable angina. J Hum Hypertens 1994; 8:635-638.
33. 33 Samani NJ, O'Toole L, Martin D, Rai H, Fletcher S, Lodwick D, et al. Insertion/deletion polymorphiam in the angiotensin-converting enzyme gene and risk of and prognosis after myocardial infarction. J Am Coll Cardiol 1996; 28:338-344.
34. 34 Gardemann A, Fink M, Stricker J, Nguyen QD, Humme J, Katz N, et al. ACE I/D gene polymorphism: presence of the ACE D allele increases the risk of coronary artery disease in younger individuals. Atherosclerosis 1998; 139:153-159. This large case-control study of coronary angiography results from 2267 male German Caucasians is an expansion of an earlier study 920 individuals reported in 1995. The expanded study was undertaken because power analysis indicated that larger samples sizes were needed to detect ACE-DD associated differences in risk for CHD. The study identified the D allele as a risk factor for coronary artery disease in young individuals and for myocardial infarction in older individuals. Data from both age groups are included in the Mantel-Haenszel calculation of European odds ratio for myocardial infarction.
35. 35 Winkelman BR, Nauck M, Klein B, Rus AP, Bohm BO, Siekmeier R, et al. Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with increased plasma angiotensin-converting enzyme activity but not with increased risk for myocardial infarction and coronary artery disease. Ann Int Med 1996; 125:19-25.
36. 36 Ahnve S, Flodin T, Berglund L, Eggertsen G, Slyven C. Angiotensin converting enzyme gene polymorphism in acute myocardial infarction patients. J Am Coll Card 1995; 25 (Suppl 2):276A-277A.
37. 37 Agerholm-Larsen B, Nordestgaard BG, Steffensen R, Sorensen TIA, Jensen G, Tybjaerg-Hansen A. ACE gene polymorphism: ischemic heart disease and longevity in 10150 individuals. Circulation 1997; 95:2358-2367.
38. 38 Bohn M, Berge KE, Erikssen J, Berg K. Insertion/deletion polymorphism at the locus for angiotensin I-converting enzyme and myocardial infarction. Clin Genet 1993; 44:292-297.
39. 39 Beohar N, Damarju S, Prather A, Yu Q-T, Raizner A, Kleiman NS, et al. Angiotensin-I converting enzyme genotype DD is a risk factor for coronary heart disease J Invest Med 1995; 43:275-280.
40. 40 Ludwig E, Corneli PS, Anderson JL, Marshall HW, Lalouel J-M, Ward OH. Angiotensin-converting enzyme gene polymorphism is associated with myocardial infarction but not with development of coronary stenosis. Circulation 1995; 91:2120-2124.
41. 41 Anderson JL, Carkquist JF, King GJ, Morrison L, Thomson MJ, Ludwig EH, et al. Angiotensin-converting enzyme genotypes and risk for myocardial infarction in women J Am Coll Cardiol 1998; 31:790-796. This case - control study of coronary angiography results from 490 American women treated at the LDS Hospital in Utah is an extension of the earlier study done by Ludwig et al. [40]. Power analysis indicated that, due to the lower incidence of CHD in women, a larger sample size was necessary to detect ACE-DD associated differences in risk for CHD in women. Because the data in this paper included the women reported on in the prior study, it was used instead of the data from women in [40], and only the data on male patients from that study were utilized in the calculation of combined odds ratio in Tables 1 and 3.
42. 42 Akar N, Aras O, Omurlu K, Cin S. Deletion polymorphism at the angiotensin-converting enzyme in Turkish patients with coronary artery disease. Scan J Clin Invest 1998; 58:491-496. This recent study found the ACE DD genotype to be associated with a markedly elevated risk for myocardial infarction and CHD in individuals from a Turkish population.
43. 43 Katsuya T, Koike G, Yee TW, Sharpe S, Jackson R, Norton R, et al. Association of angiotensinogen T235 variant with increased risk of coronary heart disease. Lancet 1995; 345:1600-1603.
44. 44 Lindpaintner K, Pfeffer MA, Kreutz R, Stampfer MJ, Grodstein F, LaMotte F, et al. A prospective evaluation of an angiotensin-converting enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med 1995; 332:706-711.
45. 45 Breslow NE, Day NE. Statistical methods in cancer research. Vol. 1. The analysis of case-control studies. IARC Scientific Publications no. 32. Lyon: International Agency for Research on Cancer; 1980.
46. 46 Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22:719-748.
47. 47 Fujisawa T, Ikegami H, Shen G-Q, Takekawa K, Nakagawa Y, Hamada Y, et al. Angiotensin I-converting enzyme gene polymorphism is associated with myocardial infraction, but not with nephropathy, in NIDDM. Diabetes Care 1995; 18:983-985.
48. 48 Yamasaki Y, Tsujino T, Kodama M, Kajimoto Y. DD genotype of the ACE gene as an atherosclerosis-independent risk factor for myocardial infarction. Circulation 1997; 96:3782.
49. 49 Ruiz J, Blanche H, Cohen N, Velho G, Cambien F, Cohen D, et al. Insertion/ deletion polymorphism of the angiotensin-converting enzyme gene is strongly associated with coronary heart disease in non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA 1994; 91 :3662-3665.
50. 50 Chuang LM, Chiu KC, Chiang FT, Lee KC, Lin BJ, Tai TY. Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene in patients with hypertension, non-insulin-dependent diabetes mellitus and coronary heart disease in Taiwan. Metabolism 1997; 46:1211-1214.
51. 51 Ukkola O, Savolainen MJ, Salmela PI, von Dickhoff K, Kesamiemi YA. Insertion/deletion polymorphism in the angiotensin-converting enzyme gene associated with macroangiopathy and blood pressure in patients with non-insulin-dependent diabetes mellitus. J Mol Med 1995; 73:307-311.
52. 52 Panahloo A, Andres C, Mohamed-Ali V, Gould MM, Talmud P, Humphries SE, Yudkin JS. The insertion allele of the ACE gene polymorphism a candidate for insulin resistance? Circulation 1995; 92:3390-3393.
53. 53 Huang X-H, Rantalaiho V, Wirta O, Pasternack H, Koivula T, Hiltunen TP, et al. Angiotensin-converting enzyme gene polymorphism is associated with coronary disease in non-insulin-dependent diabetic patients evaluated for 9 years. Metabolism 1998; 47:1258-1262. This Finnish study details the incidence of CHD in 83 newly diagnosed NIDDM patients at the beginning and end of a 9 year observation period. ACE DD genotype was shown to be positively associated with both overall CHD status at the end of the 9 year period and the development of CHD in individuals who were CHD free at the start of the study.
54. 54 Keavney BD, Dudley CRK, Stratton IM, Matthews DR, Ratcliffe PJ, Turner RC. UK Prospective Diabetes Study (UKPDS) 14: association of angiotensin-converting enzyme insertion/deletion polymorphism with myocardial infarction in NIDDM. Diabetologica 1995; 38:948-952.
55. 55 Fujisawa T, Ikegami H, Kawaguchi Y, Hamada Y, Ueda H, Shintani M, et al. Meta-analysis of association of insertion/deletion polymorphism of angiotensin-I converting enzyme with diabetic neuropathy and retinopathy. Diabetologica 1998; 41:47-55. This meta-analysis of 18 studies of 4773 diabetic patients used the Mantel-Haenszel method to calculate an overall odds ratio for diabetic nephropathy of 1.32, confidence interval 1.15-1.51, for the DD+DI versus the II ACE genotypes, which was significant for both NIDDM patients (P<0.005) and for insulin-dependent diabetics (P<0.05). No statistically significant association of the I/D polymorphism with diabetic retinopathy was observed.
56. 56 Dakik HA, Mahmarian JJ, Verani MS, Farmer JA, Zhao G, Marian AJ. Association of angiotensin I-converting enzyme gene polymorphisms with myocardial ischemia and patency of infarct-related artery in patients with acute myocardial infarction. J Am Coll Cardiol 1997; 29:1468-1473.
57. 57 O'Malley JP, Maslen CL, Illingworth DR. Angiotensin-converting enzyme DD genotype and cardiovascular disease in heterozygous familial hypercholester-olemia. Circulation 1998; 98:1780-1783. This study found that heterozygous familial hypercholesterolemia and FDB patients, who are at increased risk for CHD because of their high LDL levels, are at even greater risk if they also carry the ACE DD genotype.
58. 58 Mabuchi H, Koizumi J, Shimizu M, Takeda R. Development of coronary artery disease in familial hypercholesterolemia. Circulation 1989; 79:225-232.
59. 59 Defesche JC, Pricker KL, Phillips NR, Hayden MR, Vanderende BE, Kasteleine JJP. Familial defective apolipoprotein B-100 is clinically indistinguishable from familial hypercholesterolemia. Arch Int Med 1993; 53:2349-2356.
60. 60 Petrovic D, Kleber I, Zorc M, Peterlin B. I/D polymorphism at the locus for ACE and apo A-I gene promoter polymorphism as risk factors for coronary heart disease in patients with familial hypercholesterolemia. Pflugers Arch Eur J Physiol 1996;431 (Suppl):R197-R198.
61. 61 Nakauchi Y, Suehiro T, Yamamoto M, Yasuoka N, Arii K, Yoshitka K, et al. Significance of angiotensin I-converting enzyme and angiotensin II type 1 receptor gene polymorphisms as risk factors for coronary heart disease. Atherosclerosis 1996; 125:12:161-169.
62. 62 Morita H, Kurihara H, Taguchi J-I, Ohno M, Yazki Y. ACE and MTHFR gene polymorphisms: genetic coronary risk factors relating to different aspects of pathophysiology [letter]. Thromb Haemost 1998; 80:200-201. This recent letter to the editor summarized a Japanese study which indicated that the ACE DD is associated with an increased risk for angiographically defined stenosis in Japanese.
63. 63 Chiang F-T, Lai Z-P, Chern T-H, Tseng C-D, Hsu K-L, Lo H-M, Tseng Y-Z. Lack of association between angiotensin-converting enzyme gene polymorphism and coronary heart disease in a Chinese population. Japanese Heart J 1997; 38:227-236.
64. 64 Sama N, Talmud PJ, Tay JSH, Humphries SE, Basair J. Lack of association of angiotensin-converting enzyme (ACE) gene insertion/deletion poymorphism with CAD in two Asian populations. Clin Genet 1996; 50:121-125.
65. 65 Wang XL, McCredid RM, Wilcken DEL. Genotype distribution of angiotensin-converting enzyme polymorphism in Australian healthy and coronary populations and relevance to myocardial infarction and coronary artery disease. Arterioscler Thromb Vasc Biol 1996; 16:115-119.
66. 66 Dessi-Fulgheri P, Catalini R, Sarzani R, Sturbini S, Siragusa N, Guazzorotti F, et al. Angiotensin converting enzyme gene polymorphism and carotid atherosclerosis in a low-risk population. J Hypertens 1995; 13:1593-1596.
67. 67 Tokgozoglu SL, Alikasifoglu M, Atalar E, Tunäbilek E, Övünç K, Aksoyek S, et al. Angiotensin converting enzyme gene polymorphism and the risk and extent of ischemic heart disease among Turkish patients. Coronary Artery Dis 1997; 8:137-141.
68. 68 Ludwig EH, Borecki IB, Ellison RC, Folsom AR, Heiss G, Higgins M, et al. Associations between candidate loci angiotensin-converting enzyme and angiotensinogen with coronary heart disease and myocardial infarction: the NHLBI Family Heart Study. Ann Epidemiol 1997; 7:3-12.
69. 69 Arnett DK, Borecki IB, Ludwig EH, Pankow JS, Myers R, Evans G, et al. Angiotensinogen and angiotensin converting enzyme genotypes and carotid atherosclerosis: the atherosclerosis risk in communities and the NHLBI family studies. Atherosclerosis 1998; 138:111-116. This study examined the association of the ACE DD genotype with carotid intima-medial thickness as measured by B-mode ultrasound in 495 healthy adults from diverse regions in the USA.
70. 70 Bauters C, Amouyel P. Association between the ACE genotype and coronary artery disease. Insights from studies on restenosis, vasomotion and thrombosis. Eur Heart J 1998; 19 (Suppl J):J24-J29.
71. 71 Amant C, Bauters C, Bodart JC, Amant C, Bauters C, Bodart JC, et al. D allele of the angiotensin I-converting enzyme is a major risk factor for restenosis after coronary stenting. Circulation 1997; 96:56-60.
72. 72 Ribichini F, Steffenino G, Dellavalle S, Matullo G, Colajanni E, Camilla T, et al. Plasma activity and insertion/deletion polymorphism of angiotensin I-converting enzyme. Circulation 1998; 97:147-154.
73. 73 The Sixth Report of the Joint National Committee on Prevention, Detection and Treatment of High Blood Pressure. Arch Intern Med 1997; 157:2413-2446.
74. 74 Borghi C, Ambrosioni E. Evidence-based medicine and ACE inhibition. J Cardiovasc Pharmacol 1998; 32 (Suppl 2):S24-S35.